Evidence map›Paper›PMID 28417194›Full record

ArticleJournal of cancer research and clinical oncology2017

Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.

Jochen Hess, Patrick Stelmach, Andreas Eisenhardt, Herbert Rübben, Henning Reis, Kurt Werner Schmid, Hagen Sjard Bachmann

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jochen HessClinic of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. jochen.hess@uk-essen.de.ORCID http://orcid.org/0000-0002-9902-5368
Patrick StelmachInstitute of Pharmacogenetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Andreas EisenhardtPraxisklinik Urologie Rhein/Ruhr, Mülheim, Germany.
Herbert RübbenClinic of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Henning ReisInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Kurt Werner SchmidInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Hagen Sjard BachmannInstitute of Pharmacogenetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
University of Duisburg-Essen · DEEssen University Hospital · DEKlinik und Poliklinik für Urologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the impact of three BCL2 single-nucleotide polymorphisms, i.e., c.-938C>A (rs2279115), c.21G>A (rs1801018), and c.*2203A>G (rs4987853) on survival in patients with transitional cell carcinoma of the bladder.

methodsWe analyzed 179 patients who underwent surgical treatment for bladder cancer at the Clinic of Urology, University Hospital Essen, Germany. Genomic DNA was extracted and genotyped for the polymorphisms. For all polymorphisms, linkage analysis was performed. Kaplan-Meier and Cox regression analyses were used to determine the putative impact of the three polymorphisms on outcome.

resultsc.-938C>A and c.21G>A, but not c.*2203A>G, are in strong linkage disequilibrium (D' 0.96). We found a significant association between c.-938C>A and relapse-free survival (p = 0.024) with an allele dose effect. In the same way, c.21G>A had a significant impact on both relapse-free survival (p = 0.009) and progression-free survival (p = 0.012), as well as a pronounced allele dose effect. Regression analysis proved c.21G>A and c.-938C>A, to be an independent risk factor in univariate and multivariable analyses.

conclusionsIn our cohort, both c.-938C>A and c.21G>A showed a significant impact on outcome with TCC of the bladder. Due to the linkage disequilibrium of both SNPs, maybe, only one of them could mediate this effect. In multivariable analysis, however, both proved to be independently associated with overall survival. Contrary to other findings which found the c.-938C>A mainly influencing outcome, our data may suggest that the main effect on TCC could be due to the c.21G>A polymorphism.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overCarcinoma, Transitional CellDisease-Free SurvivalFemaleGenotypeHumansKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Urinary Bladder NeoplasmsBCL2 protein, humanProto-Oncogene Proteins c-bcl-2BCL2Bladder cancerSingle-nucleotide polymorphismSNPUrothelial carcinoma

Identifiers

PMID28417194
PMCPMC11819066
OpenAlexW2605431548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.